quinazolines has been researched along with lixazinone in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, R; Bruno, JJ; Stephenson, RA; Strosberg, AM; Venuti, MC | 1 |
| Alvarez, R; Bruno, JJ; Chiang, HS; Chu, N; Fried, JH; Gu, L; Massey, IJ; Strosberg, AM; Venuti, MC | 1 |
| Alvarez, R; Kenley, RA; Lin, LH; Venuti, MC; Visor, GC | 1 |
| Alvarez, R; Banerjee, GL; Bruno, JJ; Jones, GL; Littschwager, K; Strosberg, AM; Venuti, MC | 1 |
| Alvarez, R; Bruno, JJ; Jones, GH; Venuti, MC | 1 |
| Alvarez, R; Bruno, JJ; Johnson, L; Jones, GH; Lee, CH; Montgomery, W; Strosberg, AM; Venuti, MC | 1 |
| Dousa, TP; Grande, JP; Johnson, RJ; Shankland, SJ; Tsuboi, Y; Walker, HJ | 1 |
| Dickinson, NT; Haslam, RJ; Jang, EK | 1 |
| Dousa, TP; Grande, JP; Matousovic, K; Tsuboi, Y; Walker, H | 1 |
| Degerman, E; Kenan, Y; Manganiello, VC; Murata, T; Shakur, Y | 1 |
| Cheng, J; Grande, JP; Gray, CE; Thompson, MA; Walker, HJ; Warner, GM; Zhou, W | 1 |
11 other study(ies) available for quinazolines and lixazinone
| Article | Year |
|---|---|
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cardiotonic Agents; Dogs; Drug Evaluation; Heart Failure; Humans; Myocardium; Platelet Aggregation; Quinazolines; Structure-Activity Relationship | 1988 |
Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Biological Availability; Dogs; Drug Evaluation; Gastric Juice; Hydrogen-Ion Concentration; Intestinal Mucosa; Prodrugs; Quinazolines; Solubility | 1988 |
Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Ascorbic Acid; Cardiotonic Agents; Drug Interactions; Electrochemistry; Platelet Aggregation Inhibitors; Quinazolines; Quinolones; Solutions | 1987 |
A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Blood Pressure; Dogs; Heart Rate; Hemodynamics; Humans; Imidazoles; Macaca mulatta; Membranes; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Platelet Aggregation; Quinazolines; Quinolines; Tissue Distribution | 1986 |
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Dogs; Humans; Imidazoles; Indicators and Reagents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Myocardium; Quinazolines; Quinolines; Rats; Spectrophotometry, Infrared; Structure-Activity Relationship | 1987 |
RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties.
Topics: Animals; Dogs; Fibrinolytic Agents; Heart Rate; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Quinolines; Vasodilation | 1987 |
Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Actins; Animals; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinases; Glomerulonephritis, Membranoproliferative; Hydralazine; Isoenzymes; Kidney Function Tests; Kidney Glomerulus; Laminin; Male; Phosphodiesterase Inhibitors; Proteinuria; Pyrrolidinones; Quinazolines; Rats; Rats, Wistar; Rolipram; Superoxides | 1996 |
Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adenine; Blood Platelets; Cyclic AMP; Dideoxyadenosine; Enzyme Activation; Enzyme Inhibitors; Epoprostenol; Humans; Nitroprusside; Platelet Aggregation; Quinazolines | 1997 |
Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Division; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Down-Regulation; Folic Acid; Isoenzymes; Kidney Tubules; Male; Phosphodiesterase Inhibitors; Proliferating Cell Nuclear Antigen; Pyrrolidinones; Quinazolines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Signal Transduction; Tetrazoles | 1997 |
Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Isoenzymes; Kinetics; Mice; Mutagenesis, Site-Directed; Protein Conformation; Quinazolines; Sequence Deletion; Solubility; Structure-Activity Relationship | 2000 |
Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Cycle Proteins; Cell Line; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclin D; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dogs; Epithelial Cells; Gene Expression Regulation, Enzymologic; Kidney; Mitosis; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Quinazolines; Rolipram | 2006 |